Transcriptome analysis of the effects of sorafenib and osimertinib in PC9 cells

The aim of the study was to characterize the gene expression profiles of PC9 cells exposed to sorafenib and osimertinib, alone or in combination. PC9 cells were cultured in presence of sorafenib and osimertinib for 1day, 2 days and 4 days. Genome-wide expression profiling (Agilent microarrays) were used to characterize the transcriptome of PC9 cells and to identify specific gene exptression signatures and functionally relevant gene networks linked to sorafenib and osimertinib treatments. PC9 cells (NSCLC) were obtained from ECACC (distributed by Sigma-Aldrich). PC9 cells were grown in RPMI1640 (2Mm L-Glutamine + 25 mM HEPES) supplemented with 10% FBS. Osimertinib and sorafenib were purchased from LC Laboratories. PC9 cells were treated in triplicate with or without osimertinib (1 µM) and/or sorafenib (5 µM) for 1, 2 or 4 days (for the longest time point, the media was renewed after 2 days), and total RNA was isolated using the miRNeasy kit (Qiagen) following the manufacturer’s instructions.